Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q1 FY2021 Earnings Presentation
14 slides from Advanced Enzyme Technologies's earnings presentation, Aug 12, 2020
Slide 1: Advanced Enzyme Technologies Limited Earnings Presentation Q1FY21
Advanced Enzyme Technologies Limited Earnings Presentation | Q1FY21
Slide 2: Disclaimer
2 Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views
Slide 3: Company Overview
3 Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve effic
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
4 Advanced Enzyme Technologies Limited – A Rising Global Star Manufacturing Units – 7 R&D Units – 7 } India – 4 | USA – 1 | Germany – 2 India - 5USA - 2 REVENUE (₹ mn) 1st 2nd 2nd 4,440 Indian enzyme company Highest market share in Listed integrated 2,938 India enzyme player globally FY 16 FY 20 EBI
Slide 5: Results Summary – Q1FY21 (Consolidated)
5 Results Summary – Q1FY21 (Consolidated) *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) -3.3% 1,103 1,105 535 517 340 348 Q1FY20 Q1FY21 Q1FY20 Q1FY21 Q1FY20 Q1FY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing 19% -24% Q1FY21 106 Q1FY21 868 22% Q1FY21 (1%) 131 Q1FY20 Q
Slide 6: Revenue Split – Q1FY21
6 Revenue Split – Q1FY21 Q1FY21 Q1FY20 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 10% 15% 12% 78% 73% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 2% 3% 6% 43% 43% 47% 43% 6% 6% Asia (ex- India)
Slide 7: Profit & Loss (Consolidated) – Q1FY21
7 Profit & Loss (Consolidated) – Q1FY21 ₹ in Million except per share data Q1FY21 Q4FY20 Q1FY20 Y-o-Y FY20 FY19 Particulars Y-o-Y (%) Unaudited Audited Unaudited (%) Audited Audited Income from Operations 1,105 1,103 1,103 0.2% 4,440 4,196 6% Expenses 654 682 631 4% 2,675 2,587 3% Profit from Operat
Slide 8: Results Summary – FY20
8 Results Summary – FY20 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,440 2,023 4,196 1,819 1,330 1,159 FY19 FY20 FY19 FY20 FY19 FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% FY2 FY2 FY2 536 3,211 555 0 0 (1%) 0 FY1 FY1 FY1 493 3,133 512 9 9 9 9% 2% 8% Not
Slide 9: Revenue Split – FY20
9 Revenue Split – FY20 FY20 FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 13% 12% 12% 12% 75% 76% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 42% 49% 40% 43% 7% 5% Asia (ex- India) Others
Slide 10: Balance Sheet (Consolidated) – FY20
10 Balance Sheet (Consolidated) – FY20 ₹ in Million FY20 FY19 Particulars Audited Audited Assets Property, plant and equipment 2,042 1,618 Capital work-in-progress 101 105 Intangible assets 646 622 Goodwill 2,941 2,715 Other non-current assets 195 183 Current assets 3,813 2,820 Assets held for sale
Slide 11: Strong Financial Performance – FY20
11 Strong Financial Performance – FY20 ₹ in Million Revenue from Operations EBIDTA & EBIDTA Margin (%) 4,440 2,500 47% 43% 46% 50% 3,957 4,196 42% 48% 3,431 45% 2,000 46% 2,938 1,654 1,500 44% 1,534 2,023 1,000 1,389 42% 1,819 40% 500 38% 0 36% FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 F
Slide 12: Strong Financial Performance – FY20
12 Strong Financial Performance – FY20 Net Working Capital (Days) Net Worth (₹ mn) 8,396 119 6,788 115 5,591 112 4,640 108 105 2,781 FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 20 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.4 27% 27% 24% 21% 28% 19% 18% 19% 0.1 16% 0.01 0.02 0.00 FY
Slide 13: Shareholder Information
13 Shareholder Information Top 5 Institutional Holders (As on 07th August 2020) Stock Data (As on 11th August 2020) Institutions OS (%) ORBIMED ASIA III MAURITIUS 12.09 Market Capitalization (₹) 23,424 mn HDFC SMALL CAP FUND 6.51 Shares Outstanding 111.67 mn RELIANCE CAPITAL TRUSTEE CO. 0.68 Free Fl
Slide 14: Thank You
Thank You Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Web: www.advancedenzymes.com Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q1 FY2021 Earnings Presentation on 6ix